Cao Lei, Wang Rong, Wang Yan, Zhao Si-Shu, Yang Hui, Xu Ji, Long Qi-Qiang, He Guang-Sheng, Li Jian-Yong
Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China.
Key Laboratory of Hematology of Nanjing Medical University, Nanjing 210029, China.
Transl Cancer Res. 2020 Feb;9(2):1288-1293. doi: 10.21037/tcr.2019.12.14.
Acute basophilic leukemia (ABL), as a rare form of acute myeloid leukaemia (AML) accounts for <1% of cases of AML. ABL has not been detected for encouragingly specific targets. Here we report a de novo fragile ABL case treated with decitabine based regimen with transient response even if overall survival was a 3-month. The case of a 79-year-old male who was complained of fever, rashes and cytopenia is reported in the current study. The diagnosis of ABL was identified due to characteristic cytomorphological features and immunophenotype of myeloid blast cells without the Philadelphia chromosome. The patient initially presented with short-term improvement with decitabine. Combination of decitabine and arsenic trioxide in second chemotherapy regimen didn't reverse the end of death with a 3 months overall survival. In conclusion, our study revealed that decitabine may be an efficient therapeutic option in ABL patients and warranted much more exploration in use.
急性嗜碱性粒细胞白血病（ABL）是急性髓系白血病（AML）的一种罕见形式，占AML病例的不到1%。尚未发现ABL有令人鼓舞的特异性靶点。在此，我们报告1例初发的脆性ABL病例，采用基于地西他滨的方案治疗，虽总体生存期仅3个月，但有短暂缓解。本研究报告了1例79岁男性病例，该患者主诉发热、皮疹和血细胞减少。由于髓母细胞具有特征性的细胞形态学特征和免疫表型且无费城染色体，故确诊为ABL。患者最初用地西他滨治疗有短期改善。在第二个化疗方案中，地西他滨与三氧化二砷联合使用并未扭转死亡结局，总体生存期为3个月。总之，我们的研究表明，地西他滨可能是ABL患者的一种有效治疗选择，值得进一步探索其应用。
